

Subject index

Volume 45 (2000)

Acridone; Topoisomerase II; Antiviral 45, 123

AIDS; HIV DNA-infected cells; Viral load; HAART; HAART plus rIL-2 45, 95

Anti-EBV; Pro-nucleotides; Anti-HSV-1 45, 69

Anti-HSV-1; Pro-nucleotides; Anti-EBV 45, 69

Antiviral inhibition; Duck hepatitis B virus; Replication; Polymerase; Reverse transcriptase; Replicating cores 45, 185

Antiviral; Isothiazole derivatives; Rhinovirus 45, 199

Antiviral nucleosides; Varicella-zoster virus; Protein kinase 45, 79

Antiviral testing; Handwashing; Surgical hand disinfection; Vaccinia virus 45, 149

Antiviral therapy; Filovirus; Ebola virus; *S*-Adenosyl-L-homocysteine hydrolase 45, 135

Antiviral; Topoisomerase II; Acridone 45, 123

Atevirdine mesylate; Concentration-targeted phase I trials; Patients with HIV; Dosage studies; Pharmacokinetic studies 45, 47

Cidofovir; Ganciclovir; Resistant virus; DNA polymerase; 3'-5'exonuclease 45, 115

Combination antiviral therapy; Woodchuck Hepatitis Virus; Hepatitis B Virus; Experimental animal model; Lamivudine; Famciclovir 45, 19

Concentration-targeted phase I trials; Atevirdine mesylate; Patients with HIV; Dosage studies; Pharmacokinetic studies 45, 47

Corneal scarring; HSV-1; NK depleted mice 45, 33

DNA polymerase; Ganciclovir; Cidofovir; Resistant virus; 3'-5'exonuclease 45, 115

Dosage studies; Concentration-targeted phase I trials; Atevirdine mesylate; Patients with HIV; Pharmacokinetic studies 45, 47

Drug combinations; Reverse transcriptase; Protease; Resistance 45, 101

Drug delivery; Newcastle disease virus (NDV); HEp-2; Liposomes; Ribonuclease 45, 211

Duck hepatitis B virus; Replication; Polymerase; Reverse transcriptase; Antiviral inhibition; Replicating cores 45, 185

Ebola virus; Filovirus; Antiviral therapy; *S*-Adenosyl-L-homocysteine hydrolase 45, 135

EICAR; IPNV; GTP pool level 45, 9

3'-5'exonuclease; Ganciclovir; Cidofovir; Resistant virus; DNA polymerase 45, 115

Experimental animal model; Woodchuck Hepatitis Virus; Hepatitis B Virus; Combination antiviral therapy; Lamivudine; Famciclovir 45, 19

Famciclovir; Woodchuck Hepatitis Virus; Hepatitis B Virus; Combination antiviral therapy; Experimental animal model; Lamivudine 45, 19

Filovirus; Ebola virus; Antiviral therapy; *S*-Adenosyl-L-homocysteine hydrolase 45, 135

Ganciclovir; Cidofovir; Resistant virus; DNA polymerase; 3'-5'exonuclease 45, 115

Ganciclovir elaidic ester; HSV; Prodrug 45, 157

GTP pool level; EICAR; IPNV 45, 9

HAART; AIDS; HIV DNA-infected cells; Viral load; HAART plus rIL-2 **45**, 95

HAART plus rIL-2; AIDS; HIV DNA-infected cells; Viral load; HAART **45**, 95

Handwashing; Surgical hand disinfection; Antiviral testing; Vaccinia virus **45**, 149

Hepatitis B virus; Human immunodeficiency virus; β -L-Dideoxynucleoside enantiomers; Pronucleotides **45**, 169

Hepatitis B Virus; Woodchuck Hepatitis Virus; Combination antiviral therapy; Experimental animal model; Lamivudine; Famciclovir **45**, 19

HEp-2; Newcastle disease virus (NDV); Liposomes; Ribonuclease; Drug delivery **45**, 211

HIV DNA-infected cells; AIDS; Viral load; HAART; HAART plus rIL-2 **45**, 95

HIV-1 infectivity; HIV-1 protease inhibitors; Pr160^{gag-pol} processing **45**, 59

HIV-1 protease inhibitors; HIV-1 infectivity; Pr160^{gag-pol} processing **45**, 59

HSV; Ganciclovir elaidic ester; Prodrug **45**, 157

HSV-1; NK depleted mice; Corneal scarring **45**, 33

Human immunodeficiency virus; Hepatitis B virus; β -L-Dideoxynucleoside enantiomers; Pronucleotides **45**, 169

Human papillomavirus; Laryngeal papillomatosis; Recurrent respiratory papillomatosis **45**, 83

IPNV; EICAR; GTP pool level **45**, 9

Isothiazole derivatives; Antiviral; Rhinovirus **45**, 199

Lamivudine; Woodchuck Hepatitis Virus; Hepatitis B Virus; Combination antiviral therapy; Experimental animal model; Famciclovir **45**, 19

Laryngeal papillomatosis; Human papillomavirus; Recurrent respiratory papillomatosis **45**, 83

β -L-Dideoxynucleoside enantiomers; Human immunodeficiency virus; Hepatitis B virus; Pronucleotides **45**, 169

Liposomes; Newcastle disease virus (NDV); HEp-2; Ribonuclease; Drug delivery **45**, 211

Newcastle disease virus (NDV); HEp-2; Liposomes; Ribonuclease; Drug delivery **45**, 211

NK depleted mice; HSV-1; Corneal scarring **45**, 33

Patients with HIV; Concentration-targeted phase I trials; Ateviridine mesylate; Dosage studies; Pharmacokinetic studies **45**, 47

Pharmacokinetic studies; Concentration-targeted phase I trials; Ateviridine mesylate; Patients with HIV; Dosage studies **45**, 47

Polymerase; Duck hepatitis B virus; Replication; Reverse transcriptase; Antiviral inhibition; Replicating cores **45**, 185

Pr160^{gag-pol} processing; HIV-1 protease inhibitors; HIV-1 infectivity **45**, 59

Prodrug; HSV; Ganciclovir elaidic ester **45**, 157

Pro-nucleotides; Anti-HSV-1; Anti-EBV **45**, 69

Pronucleotides; Human immunodeficiency virus; Hepatitis B virus; β -L-Dideoxynucleoside enantiomers **45**, 169

Protease; Reverse transcriptase; Drug combinations; Resistance **45**, 101

Protein kinase; Varicella-zoster virus; Antiviral nucleosides **45**, 79

Recurrent respiratory papillomatosis; Human papillomavirus; Laryngeal papillomatosis **45**, 83

Replicating cores; Duck hepatitis B virus; Replication; Polymerase; Reverse transcriptase; Antiviral inhibition **45**, 185

Replication; Duck hepatitis B virus; Polymerase; Reverse transcriptase; Antiviral inhibition; Replicating cores **45**, 185

Resistance; Reverse transcriptase; Protease; Drug combinations **45**, 101

Resistant virus; Ganciclovir; Cidofovir; DNA polymerase; 3'-5'exonuclease **45**, 115

Reverse transcriptase; Duck hepatitis B virus; Replication; Polymerase; Antiviral inhibition; Replicating cores **45**, 185

Reverse transcriptase; Protease; Drug combinations; Resistance **45**, 101

Rhinovirus; Isothiazole derivatives; Antiviral **45**, 199

Ribonuclease; Newcastle disease virus (NDV); HEp-2; Liposomes; Drug delivery **45**, 211

S-Adenosyl-L-homocysteine hydrolase; Filovirus; Ebola virus; Antiviral therapy **45**, 135

Surgical hand disinfection; Handwashing; Antiviral testing; Vaccinia virus **45**, 149

Topoisomerase II; Acridone; Antiviral **45**, 123

Vaccinia virus; Handwashing; Surgical hand disinfection; Antiviral testing **45**, 149

Varicella-zoster virus; Protein kinase; Antiviral nucleosides **45**, 79

Viral load; AIDS; HIV DNA-infected cells; HAART; HAART plus rIL-2 **45**, 95

Woodchuck Hepatitis Virus; Hepatitis B Virus; Combination antiviral therapy; Experimental animal model; Lamivudine; Fanciclovir **45**, 19